Effectively there are no competitors - that is why the FDA has granted orphan status for Dimerix' DMX-200 combo (propagermanium+irbesartan).. Current standard of care is irbesartan, which is off-license (generic is available). Irbesartan was originally developed to treat high blood pressure I believe.
Ann: AGM Presentation, page-34
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
-0.005(0.99%) |
Mkt cap ! $305.0M | |||
| Open | High | Low | Value | Volume |
| 53.5¢ | 56.0¢ | 49.5¢ | $4.474M | 8.387M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52809 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 61477 | 3 |
View Market Depth
| Last trade - 12.53pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
50.5¢ |
Change
-0.005 ( 0.12 %) |
||||
| Open | High | Low | Volume | ||
| 53.5¢ | 56.0¢ | 49.5¢ | 5070506 | ||
| Last updated 13.10pm 04/06/2024 ? | |||||
| DXB (ASX) Chart |